free porn
porn
free porn

News


News-Icon_115_websiteArticles and press releases related to the conference can be found here. Please check back periodically to find recent news on the presenting companies, sponsors and co-hosts as well as ARM press releases.

Presenting Company & Sponsor News

Cardio3 BioSciences Acquires Corquest Medical Inc.

November 5, 2014 – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today that it has acquired U.S.-based CorQuest Medical Inc. CorQuest Medical specializes in the development of innovative devices and technologies for cardiac surgery.

Read more >

Kiadis Pharma’s Lead Product ATIR™ Granted Orphan Drug Designation by EMA for the Treatment of Acute Myeloid Leukemia

October 30, 2014 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that its lead product ATIR™ has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of acute myeloid leukemia (AML). Kiadis Pharma has previously been granted an ODD for ATIR™ by both the EMA and the FDA for the prevention of acute Graft-versus-Host-Disease (GvHD) following an allogeneic bone marrow transplantation.

Read more >

TxCell Achieves Positive Results
for Col-Treg in a Model of Autoimmune Uveitis

October 28, 2014 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options.

Read more >

NeoStem Announces BioProcess International Excellence in Leadership Award Given to Dr. Robert Preti, Chief Scientific Officer and President of PCT

October 27, 2014 – NeoStem, Inc. (Nasdaq:NBS), (“NeoStem” or the “Company”) a leader in the emerging cellular therapy industry, announced today that Dr. Robert Preti, the Company’s Chief Scientific Officer and President of its subsidiary, Progenitor Cell Therapy (“PCT”), was honored with the Excellence in Leadership award at the 2014 BioProcess International (“BPI”) Awards. The recognition was announced by BPI during a special awards reception on October 22nd at the BioProcess International Conference and Exhibition at the Hynes Convention Center in Boston, Massachusetts.

Read more >

Case Western Reserve University to Study Pluristem’s PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases

October 27, 2014 – Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PLTR), a leading developer of placenta-derived cell therapy products, announced today that researchers at Case Western Reserve University will conduct a preclinical study of the Company’s PLacental eXpanded (PLX)-RAD cells. The study will evaluate whether PLX-RAD cells increase the success rate of human umbilical cord blood transplantation.

Read more >

Cardio3 BioSciences Appoints Dr. Warren Sherman as Chief Medical Officer

October 23, 2014 – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the appointment of Dr. Warren Sherman as Chief Medical Officer, effective as of 1 November 2014. In this new role, Dr. Sherman will leverage his deep expertise in the cardiovascular and cell therapy fields to support the continued development of Cardio3 BioSciences’ product pipeline, both in cell therapies and cardiovascular diseases.

Read more >

Pluristem Advances its Second Major Cell Therapy Product Line from Development to Large-Scale Manufacturing

October 21, 2014 – Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR), a leading developer of placenta-based cell therapy products, announced today that it has completed development of its second major product line, and can now begin manufacturing the cells on a large-scale at its state-of-the art facility in order to meet demand for anticipated studies in a range of hematologic conditions. This second cell product candidate, called PLX-RAD, was created using Pluristem’s proprietary three dimensional cellexpansion technology platform. The Company’s first product, PLX-PAD, is already in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary arterial hypertension.

Read more >

Adaptimmune Announces Interim Results from Pilot Trial of its Engineered NY-ESO T Cells
Targeting Synovial Sarcoma

October 17, 2014 – Adaptimmune Limited, a leading biotechnology company focused on the use of T-cell therapy to treat cancer and infectious disease, today announces the release of interim results from a pilot clinical trial 04511 of NY-ESOc259T which uses a patient’s own T cells that have been genetically altered to attack synovial sarcoma cells.

Read more >

Promethera Biosciences Receives Approval in Belgium to Enroll Patients in the Imminent HEP002 Phase IIb/III Clinical Trial

October 15, 2014 – Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of both orphan liver-based metabolic diseases and acquired liver diseases, today announces that Belgium has authorized the conduct of a trial designed to treat paediatric patients with urea cycle disorders (UCD) in a Phase IIb/III study (HEP002).

Read more >

Cardio3 BioSciences Receives Authorization to Enroll Patients in Switzerland in Its Phase III Clinical Trial CHART-1

October 13, 2014 – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure® in Switzerland.

Read more >

Oxford BioMedica Acquires Windrush Court Office and Laboratory Facilities

October 13, 2014 – Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene and cell therapy company, announces that it has acquired the freehold of the Windrush Court office and laboratory facilities in Transport Way, Oxford, England, for a total cash consideration of £3.2 million from Oxford Real Estate Owner No. 2 Limited.

Read more >

NeoStem Ranked as One of the Fastest Growing Companies in New York City

October 13, 2014 – NeoStem, Inc. (NASDAQ:NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy industry, announced today that the Company has been named one of the fastest growing companies from 2010 to 2013 located in the New York City area according to Crain’s New York Business’ Fast 50. This designation is part of Crain’s New York Business’ annual recognition of companies that have excelled in developing and implementing effective growth strategies in the New York City area.

Read more >

Oxford BioMedica Announces New Process Development and Manufacturing Collaboration Which Includes LentiVector® Licence Agreement

October 10, 2014 – Oxford BioMedica plc (LSE: OXB), (“OXB” or “the Group”) a leading gene and cell therapy company, announces today that it has signed further contracts with Novartis which build on the collaboration with Novartis announced in May 2013.

Read more >

Bone Therapeutics Extends ALLOB® Phase I/IIa Trial to Germany

October 9, 2014 – Bone Therapeutics, the regenerative therapy company addressing unmet medical needs in the fields of bone diseases and orthopaedics, announces today that its phase I/IIa trial with the allogeneic1 osteoblastic cell therapy product ALLOB® for the treatment of delayed union fractures has been approved by the Paul-Ehrlich-Institute, the national authority in Germany.

Read more >

Adaptimmune Wins OBN Best New Biotech Development Programme of 2014

October 6, 2014 – Adaptimmune Limited, a leading biotechnology company focused on the use of T-cell therapy to treat cancer and infectious disease, has won the Best New Biotech Development Programme Award of 2014 at the OBN annual awards.

Read more >

NeoStem Announces USAN Approval of Generic Name ‘Eltrapuldencel-T’ for Investigational Patient-Specific Targeted Cancer Immunotherapy

October 6, 2014 – NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that the United States Adopted Name Council (USAN) has approved the generic name “eltrapuldencel-T” for the Company’s patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma. This investigational treatment, planned to be evaluated in the Company’s Phase 3 Intus study, has been granted Orphan Drug, and Fast Track designations by the U.S. Food and Drug Administration and will be conducted under a protocol that has been granted Special Protocol Assessment (SPA). NeoStem plans to begin the trial by the end of 2014.

Read more >

Cardio3 BioSciences Announces New Business Development Strategy to Broaden its Product Pipeline

October 1, 2014 – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today that it has recently increased its business development activities, building on its core expertise in cellular therapies and in cardiovascular diseases.

Read more >

Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan

October 1, 2014 – Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported that its Japanese partner, JCR Pharmaceuticals Co Ltd (JCR), has filed with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to receive approval for manufacturing, marketing, and product registration of the allogeneic or “off-the-shelf” Mesenchymal Stem Cell (MSC) product JR-031 for the treatment of acute graft versus host disease (GVHD) in children and adults.

Read more >

MolMed Completed the First Tranche of the Share Capital Increase Reserved to Société Générale Pursuant to the Agreement Named “SEF – Standby Equity Facility”

September 29, 2014 – Following the press release published on 26 September 2014, MolMed S.p.A. (MLM.MI) (“MolMed” or the “Company”) announces the settlement of the first tranche (the “First Tranche”) of the share capital increase against payment, in one or more tranches, in divisible form, by and no later than 31 July 2016, without pre-emptive rights pursuant to Article 2441, fourth paragraph, second sentence of the Italian Civil Code, reserved to Société Générale (“SG”) in the context of the agreement named “SEF – Standby Equity Facility” entered into on 31 July 2014 between the Company and the same SG (the “Agreement”).

Read more >

Adaptimmune Secures $104 Million in Series A Financing

September 25, 2014 – Adaptimmune Limited, a leading biotechnology company focused on the use of T-cell therapy to treat cancer and infectious disease, today announced the completion of a $104 million Series A financing round.

Read more >

FierceBiotech’s 2014 Fierce 15

September 22, 2014 – A few things struck us while gathering this year’s class of the Fierce 15, our 12th annual take on some of the most noteworthy private biotech upstarts making headway these days.

FierceBiotech Names Adaptimmune as One of Its “Fierce 15” Biotech Companies of 2014

September 22, 2014 – Adaptimmune today announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Read more >

Pluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market

September 16, 2014 – Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PLTR), a leading developer of placenta-based cell therapy products, announced today it is evaluating strategic opportunities to co-develop and commercialize its PLacental eXpanded (PLX) cell therapies in Japan.

Cardio3 BioSciences Receives Approval for the Continuation of Its CHART-1 Phase III Clinical Trial from the DSMB

September 15, 2014 – Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and NYSE Euronext Paris: CARD), leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it has received the recommendation of the Data Safety and Monitoring Board (DSMB) to continue the CHART-1 clinical trial according to the original protocol. The recommendation is based on a planned analysis performed on all patient safety data available as per mid-August 2014.

Read more >

Bone Therapeutics Receives Clearance for ALLOB Phase II Trial in Spinal Fusion

September 15, 2014 – Bone Therapeutics, the regenerative therapy company addressing unmet medical needs in the fields of bone diseases and orthopaedics, announces today that it has received clearance from the Competent Authorities and Central Ethics Committee in Belgium for a phase II proof-of-concept study to assess safety and efficacy of its allogeneic1 osteoblastic cell therapy product ALLOB® in spinal fusion procedures for degenerative lumbar disc disease.

Read more >

Cancer Research UK, Cancer Research Technology and Asterias Biotherapeutics Partner to Trial Immunotherapy Vaccine for Lung Cancer

September 11, 2014 – Cancer Research UK and Cancer Research Technology (CRT), the charity’s development and commercialisation arm,have reached an agreement with Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias’ novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.

Read more >

NeoStem Announces Licensing of Patent Portfolio from The Rockefeller University Expanding its Cancer Immunotherapy Intellectual Property Portfolio

September 11, 2014 – NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that the Company has entered into an exclusive license agreement with The Rockefeller University for patented technologies that further expand the Company’s intellectual property portfolio associated with its Targeted Cancer Immunotherapy Program.

Read more >

Appointment of Chief Executive Officer

September 8, 2014 – ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, announces the appointment of Olav Hellebø, a highly experienced pharmaceutical executive, as the Company’s new Chief Executive Officer, with immediate effect.

Read more >

European Medicines Agency Accepts TiGenix Paediatric Investigation Plan for Cx601

September 8, 2014 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, announced today that the Paediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company’s Paediatric Investigation Plan (PIP) for Cx601, a locally injected stem cell product in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn’s disease.

Read more >

United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem’s PLX-PAD Cells for Treatment of Pulmonary Arterial Hypertension

September 8, 2014 – Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR), a leading developer of placenta-based cell therapy products, announced today that its licensee, United Therapeutics Corporation, has completed the dosing of the first cohort of patients in its Phase I study using Pluristem’s PLacental eXpanded (PLX-PAD) cells in patients diagnosed with pulmonary arterial hypertension (PAH).

Read more >

Bone Therapeutics Supports Pioneering Research by Backing Projects Vital to Regenerative Medicine Research

September 2014 – Bone Therapeutics, the regenerative therapy company addressing unmet medical needs in the field of bone diseases and orthopaedics, is supporting several nationwide pioneering research projects in Belgium that will provide significant value to the field of regenerative medicine.

Read more >

TxCell Granted Five New Patents in Major Global Territories for Core Technology and ASTrIA Platform Since January 2014

August 27, 2014 – TxCell SA, a biotech developing innovative,personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, today announces that five new patents for their technologies have been issued in the United States, Asia and Australia since the beginning of 2014.

Read more >

Mesoblast Unveils Path to Bring Its Key Products to Market

August 26, 2014 – Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported 2014 financial results and unveiled its strategy to prioritize and bring to market clinically differentiated products based on its proprietary Mesenchymal Precursor or Stem Cell (MPC or MSC) technologies.

Read more >

Medipost, Lung Disease Stem Cell Treatment Drug ‘Pneumostem’ Application for US Clinical Trial

August 12, 2014 – Medipost submitted phase 1 and 2 clinical trial application for premature child bronchial pulmonary dysplasia preventive treatment drug ‘Pneumostem’ to US FDA through a US company on 12 August 8.

Read more >

uniQure Acquires Cardiology Gene Therapy Company InoCard

August 11, 2014 – uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard has developed a novel gene therapy to preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF), a rapidly progressing disease affecting 26 million people worldwide.

Read more >

Chiesi and uniQure Provide Update on Glybera® Launch

August 4, 2014 – uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard has developed a novel gene therapy to preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF), a rapidly progressing disease affecting 26 million people worldwide.

Read more >

Israel’s Ministry of Health Approves Pluristem’s Commercial-Scale 3D Cell Manufacturing Process Used at Its New Haifa Facility

July 31, 2014 – Pluristem Therapeutics, Inc. (NasdaqCM: PSTI,  TASE: PLTR), a leading developer of placenta-based cell therapies, announced today that  it has completed the approval process and received final clearance from a fifth regulatory agency for its 3D cell therapy manufacturing processes in use at its new facility in Haifa. The latest approval comes from Israel’s Ministry of Health and follows similar clearances from the U.S. Food and Drug Administration, the European Union’s Qualified Person, Germany’s Paul Ehrlich Institute, and the South Korean Ministry of Food and Drug Safety.

Read more >

Bone Therapeutics and Partners Awarded Over €0.5 Million M-ERA.net Research Funding to Develop 3-D Patient-Tailored Bone Tissue Engineered Products

July 17, 2014 – Bone Therapeutics, the regenerative therapy company addressing unmet medical needs in the field of bone diseases and orthopaedics, today announces it will lead an expert consortium which has been awarded an M-ERA.net grant totaling €576,000. The M-ERA.net EU fund supports European research collaboration programmes in materials science and engineering and health-related technology innovation.

Read more >

Medipost, Stem Cell Drug ‘Cartistem’ Treatment Japanese Patent

July 10, 2014 – Medipost disclosed on 10 July that they obtained patent from the Japanese Patent Office in relation to ‘Composition for treatment of articular cartilage damage’ which is the main technology of formulation of cartilage regeneration drug ‘Cartistem’.

Read more >

Cardio3 BioSciences Announces Secondary Placement With New Institutional Investors

July 9, 2014 ‐ Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, today announces the addition of six Swiss institutional funds to its shareholder base.

Read more >

Pluristem Initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial

July 8, 2014 – Pluristem Therapeutics, Inc. (NasdaqCM: PSTI) TASE: PLTR), a leading developer of placenta-based cell therapies, today announced the  initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC). Patient screening is now underway at three clinical centers, making South Korea the fourth country to participate in this randomized, double-blind, placebo-controlled Phase II Trial. The trial has been ongoing at clinical sites in the U.S., Israel and Germany with an enrollment target of 150 patients.

Read more >

Cardio3 BioSciences to Enroll the 120th Patient for its CHART-1 Study

July 7, 2014 – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, announces today that it has enrolled the 120th patient in its phase III clinical study CHART-1, aimed at evaluating the potential of its product candidate C-Cure® for the treatment of heart failure. This represents the half of patients to be recruited into CHART-1.

Read more >

Cardio3 BioSciences Announces Completion of its Capital Increase of €25 Million at €44 Per Share

July 1, 2014 – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, today announces the completion of a capital increase of €25 million at €44 a share initiated on 16 June 2014. The capital increase was fully subscribed on 16 June 2014 and occurred in two tranches of €12.5 million each. All new shares are subscribed for by Medisun International Limited, a investment holding company based in Hong Kong.

Read more >

European Medicines Agency Renews Marketing Authorisation for ChondroCelect

July 1, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that the Committee for Medicinal Products for Human Use (CHMP) has renewed for an additional five years its marketing authorisation for ChondroCelect in all of the 31 countries of the European Union (EU) and European Economic Area (EEA).

Read more >